Welcome to our dedicated page for Caris Life Sciences SEC filings (Ticker: CAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caris Life Sciences, Inc. filings document financial results, governance matters, financing arrangements and material company events for an AI TechBio precision medicine business. Form 8-K disclosures report quarterly and annual operating results, molecular profiling services revenue, clinical therapy selection activity, and Regulation FD updates tied to company presentations and diagnostic-development programs.
The company’s SEC record also includes a definitive proxy statement covering annual meeting proposals, director elections and auditor ratification. Other material-event filings describe senior secured credit facilities with subsidiary guarantees, amendments to bylaws affecting shareholder derivative proceedings, and capital-structure terms relevant to Caris’ public-company reporting obligations.
Caris Life Sciences, Inc. reported results of its 2026 Annual Meeting of Shareholders held on June 4, 2026. Shareholders elected ten directors to serve until the 2027 annual meeting and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
As of the April 9, 2026 record date, 282,662,545 common shares were issued, outstanding and eligible to vote, and 273,714,520 shares were represented at the meeting, constituting a quorum. Each director nominee received more votes for than withheld, and the auditor ratification proposal received substantially more votes for than against or abstaining.
POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director George Poste reported routine equity compensation and a prior ownership reclassification. He received 1,600 shares of common stock as a grant in lieu of cash 2026 board retainer fees, based on a ten-day average price of $15.62 per share. After this award, he holds 17,729 shares directly. A previous transfer of 204,108 shares from direct ownership into a family trust contributed to an indirect total of 511,702 shares, and did not change his overall beneficial ownership.
Knowles Jonathan Kenneth Charles reported acquisition or exercise transactions in this Form 4 filing.
Caris Life Sciences director Jonathan Kenneth Charles Knowles received 1,600 shares of Common Stock on May 29, 2026 as a stock grant. The shares were issued in lieu of cash compensation for his 2026 board retainer fees, based on a ten-day volume weighted average price calculation. Following this award, he directly owns 308,979 shares of Caris Life Sciences common stock.
Caris Life Sciences executive John Russel Denton reported routine equity compensation activity. On May 15, 2026, 6,047 shares of common stock were withheld at $15.25 per share to cover taxes on the vesting and settlement of RSUs, a non‑market tax-withholding disposition coded "F".
Following this event, Denton directly held 181,515 shares of common stock and indirectly held 9,184 shares through a trust. The filing shows no open-market purchases or sales, indicating a compensation-related adjustment rather than a discretionary trade.
Caris Life Sciences executive Luke Thomas Power used company stock to cover taxes on vested RSUs. On this Form 4, 9,771 shares of Common Stock were withheld at $15.25 per share to pay withholding taxes. After this tax-withholding disposition, he directly holds 153,771 shares.
Caris Life Sciences, Inc. president David Baxley Spetzler reported a routine tax-withholding disposition related to vested RSUs. On the transaction date, 13,856 shares of common stock were withheld at $15.25 per share to cover taxes, leaving him with 530,083 shares owned directly after the transaction.
Caris Life Sciences director Brian J. Brille reported routine equity compensation-related activity involving company common stock. On May 15, 2026, 13,987 shares of common stock were withheld at $15.25 per share to cover taxes on the vesting and settlement of RSUs, which is a tax-withholding disposition rather than an open-market sale.
After this tax withholding, Brille directly held 230,303 shares of common stock. In addition, a family trust held 500,000 shares of common stock, reflecting indirect ownership after previously separate family trusts were consolidated into a single trust. Brille disclaims beneficial ownership of these trust-held shares except to the extent of his pecuniary interest.
Caris Life Sciences director and major holder David D. Halbert reported a routine share disposition tied to equity compensation. On the vesting and settlement of restricted stock units (RSUs), 40,712 shares of Common Stock were withheld at $15.25 per share to cover tax obligations, which is recorded as a tax-withholding disposition rather than an open-market sale.
After this event, Mr. Halbert directly holds 2,574,533 shares of Common Stock. In addition, entities associated with him collectively hold 121,025,002 shares indirectly, including interests in Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd., Caris Investment III Ltd., and Halbert Family Capital, LLC, with Mr. Halbert disclaiming beneficial ownership except to the extent of his pecuniary interest.
CARIS LIFE SCIENCES, INC. Schedule 13G/A (Amendment No. 2) discloses joint reporting by TSSP Sub-Fund HoldCo, LLC and Alan Waxman regarding beneficial ownership of Common Stock. As of March 31, 2026, the filing bases percentages on 282,579,919 shares outstanding as of February 26, 2026.
The cover data show Sub-Fund HoldCo with 13,666,128 shares (listed shared voting and dispositive power) representing 4.8% and Alan Waxman with 14,385,399 shares (listed shared voting and dispositive power) representing 5.1%. The filing describes layers of entity ownership and management relationships and includes joint filing and authorization exhibits.
Caris Life Sciences, Inc. (CAI) ownership update: J.H. Whitney VI, L.P. and affiliated reporting persons state beneficial ownership of 18,256,615 shares of common stock, representing 6.5% of the class. The filing attributes shared voting and dispositive power over those shares to the reporting entities.
The statement lists J.H. Whitney Equity Partners VI, LLC as the sole general partner and names Paul R. Vigano and Robert M. Williams Jr. as managing members; no other person is reported to have rights to dividends or sale proceeds.